Silexion Therapeutics Corp. (SLXN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer
Silexion Therapeutics Corp. SLXN released data on Wednesday from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces primary tumor growth and metastatic spread.
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics Corp. SLXN revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Silexion Therapeutics Corp. SLXN stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.
Silexion Therapeutics Corp. (SLXN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Silexion Therapeutics Corp. ever had a stock split?
Silexion Therapeutics Corp. Profile
| Biotechnology Industry | Healthcare Sector | Ilan Hadar CEO | NASDAQ (CM) Exchange | G1281K130 CUSIP |
| IL Country | 11 Employees | - Last Dividend | 29 May 2026 Last Split | - IPO Date |
Overview
Silexion Therapeutics LTD is a distinguished biopharmaceutical entity dedicated to the discovery and development of innovative RNA interference (RNAi)-based therapeutics specifically designed to combat malignant solid tumors. Founded in 2008 and rooted in Jerusalem, Israel, the company has distinguished itself through its pioneering work in cancer treatment, leveraging its proprietary LODER (Local Drug EluteR) delivery platform to target solid tumors with high precision and efficacy. This technological innovation allows for the localised release of RNAi drugs directly into the tumor, promising a new era in targeted cancer therapy. Silexion Therapeutics’ endeavors embody a strategic approach to oncology, focusing on diseases with significant unmet medical needs, thereby positioning itself at the forefront of cancer research and treatment.
Products and Services
- SiG12D-LODER:
- Prostate-LODER:
- GBM-LODER:
This leading product has successfully concluded pre-clinical studies and has advanced through an open-label Phase I clinical trial specifically for the treatment of pancreatic cancer. SiG12D-LODER encapsulates a promising approach to addressing one of the most challenging and lethal forms of cancer, leveraging the LODER platform to deliver targeted RNAi therapy directly into the pancreatic tumor in a controlled manner.
Currently in the pre-clinical stage, Prostate-LODER represents Silexion Therapeutics’ targeted therapeutic approach to prostate cancer. By utilizing the proprietary LODER technology, this product aims to provide a novel form of treatment that could potentially transform the therapeutic landscape for prostate cancer, offering a more focused and less invasive option compared to conventional methods.
GBM-LODER is in the pre-clinical trial phase, designed to target Glioblastoma Multiform (GBM), a highly aggressive and malignant primary brain tumor. This product harnesses the power of RNAi therapy through the LODER platform, targeting the genetic aberrations within the GBM tumor cells. The aim is to provide a groundbreaking treatment that could significantly improve outcomes for patients suffering from this formidable form of brain cancer.
